Para citar este trabalho use um dos padrões abaixo:
Neglected diseases are caused by infectious and parasitic agents. These diseases are prevalent in tropical areas and poor and in developing countries have been presenting medical relevance. Among the negleted diseases, Chagas’ disease is endemic in Latin America and has spread to other continents by migratory movements. Actually, there are only two drugs available to the treatment - Nifurtimox and Benznidazole, but they are effective only in the acute phase of disease and they present several side effects. The research of new antichagasic agents at the national and international levels and in the majority carried out academically, no therapeutic alternatives for the disease have been found yet, thus persisting the urgent need for the discovery and development of new antichagasic agents. The currently strategy in drug discovery involves the choice and selection a specific biochemistry target. In case, sirtuin 2 (silent information regulator 2) were shown to be essential for the in vitro growth of T. cruzi. As reported that trypanosomatids in general, overexpression of Sir2 is related to the survival of amastigotes forms. Sir2 inhibitors like sirtinol showed efficacy against T. cruzi growth. Thus, these evidences indicate that the Sir2 of trypanosomatids can be considered as biological targets in the search and development of new antichagasic drugs. In this study we used ligand based drug design (LBDD) to planning sirtinol analogues Sir2 candidates. To understand the correlation among 12 designed analogues and Sir2 protein were performed docking studies in the Sir2 model preview models constructed by our group. These analogues were built substituting 1-phenylethanamine for other primary amines. The docking studies show that the analogues are presenting a good complementarity with Sir2 active site. These results suggest that new designed molecules can be Sir2 inhibitors and antichagasic candidates.
Com ~200 mil publicações revisadas por pesquisadores do mundo todo, o Galoá impulsiona cientistas na descoberta de pesquisas de ponta por meio de nossa plataforma indexada.
Confira nossos produtos e como podemos ajudá-lo a dar mais alcance para sua pesquisa:
Esse proceedings é identificado por um DOI , para usar em citações ou referências bibliográficas. Atenção: este não é um DOI para o jornal e, como tal, não pode ser usado em Lattes para identificar um trabalho específico.
Verifique o link "Como citar" na página do trabalho, para ver como citar corretamente o artigo